Time-dependent effect of combination therapy with erythropoietin and granulocyte colony-stimulating factor in a mouse model of hypoxic-ischemic brain injury

被引:0
作者
Ji Hea Yu
Jung Hwa Seo
Jong Eun Lee
Ji Hoe Heo
Sung-Rae Cho
机构
[1] Yonsei University College of Medicine,Department and Research Institute of Rehabilitation Medicine
[2] Yonsei University,Brain Korea 21 PLUS Project for Medical Science
[3] Yonsei University,Graduate Program of Nano Science and Technology
[4] Yonsei University College of Medicine,Department of Anatomy
[5] Yonsei University College of Medicine,Department of Neurology
[6] Yonsei University College of Medicine,Yonsei Stem Cell Center, Avison Biomedical Research Center
[7] Yonsei University College of Medicine,Rehabilitation Institute of Neuromuscular Disease
来源
Neuroscience Bulletin | 2014年 / 30卷
关键词
erythropoietin; granulocyte colonystimulating factor; hypoxia-inducible factor-1; hypoxicischemic brain injury;
D O I
暂无
中图分类号
学科分类号
摘要
Erythropoietin (EPO) and granulocyte colonystimulating factor (G-CSF) are likely to play broad roles in the brain. We investigated the effects of combination therapy with EPO and G-CSF in hypoxicischemic brain injury during the acute, subacute, and chronic phases. A total of 79 C57BL/6 mice with hypoxic-ischemic brain injury were randomly assigned acute (days 1–5), subacute (days 11–15) and chronic (days 28–32) groups. All of them were treated with G-CSF (250 μg/kg) and EPO (5 000 U/kg) or saline daily for 5 consecutive days. Behavioral assessments and immunohistochemistry for angiogenesis, neurogenesis, and astrogliosis were performed with an 8-week follow-up. Hypoxia-inducible factor-1 (HIF-1) was also measured by Western blot analysis. The results showed that the combination therapy with EPO and G-CSF in the acute phase significantly improved rotarod performance and forelimb-use symmetry compared to the other groups, while subacute EPO and G-CSF therapy exhibited a modest improvement compared with the chronic saline controls. The acute treatment significantly increased the density of CD31+ (PECAM-1) and α-smooth muscle actin+ vessels in the frontal cortex and striatum, increased BrdU+/PSANCAM+ neurogenesis in the subventricular zone, and decreased astroglial density in the striatum. Furthermore, acute treatment significantly increased the HIF-1 expression in the cytosol and nucleus, whereas chronic treatment did not change the HIF-1 expression, consistent with the behavioral outcomes. These results indicate that the induction of HIF-1 expression by combination therapy with EPO and G-CSF synergistically enhances not only behavioral function but also neurogenesis and angiogenesis while decreasing the astroglial response in a timedependent manner.
引用
收藏
页码:107 / 117
页数:10
相关论文
共 206 条
  • [1] Hasselblatt M(2007)Granulocyte-colony stimulating factor (G-CSF) and G-CSF receptor expression in human ischemic stroke Acta Neuropathol 113 45-51
  • [2] Jeibmann A(2011)Systemic G-CSF treatment does not improve long-term outcomes after neonatal hypoxic-ischaemic brain injury Exp Neurol 230 67-74
  • [3] Riesmeier B(2002)Neuronal replacement from endogenous precursors in the adult brain after stroke Nat Med 8 963-970
  • [4] Maintz D(2007)Colony stimulating factors (blood growth factors) are promising but unproven for treating stroke Stroke 38 1997-1998
  • [5] Schabitz WR(2010)Erythropoietin in stroke: quo vadis Expert Opin Biol 10 937-949
  • [6] Schlager GW(2001)Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress Proc Natl Acad Sci U S A 98 4044-4049
  • [7] Griesmaier E(2004)Derivatives of erythropoietin that are tissue protective but not erythropoietic Science 305 239-242
  • [8] Wegleiter K(2004)Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats Stroke 35 1732-1737
  • [9] Neubauer V(2004)Erythropoietin therapy for acute stroke is both safe and beneficial Mol Med 8 495-505
  • [10] Urbanek M(2009)Recombinant human erythropoietin in the treatment of acute ischemic stroke Stroke 40 e647-656